Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Blueprint Medicines Corp
(NQ:
BPMC
)
94.74
+3.40 (+3.72%)
Streaming Delayed Price
Updated: 2:41 PM EDT, May 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Blueprint Medicines Corp
< Previous
1
2
3
4
5
Next >
SVB Leerink Maintains Market Perform Rating for Blueprint Medicines: Here's What You Need To Know
June 13, 2022
SVB Leerink has decided to maintain its Market Perform rating of Blueprint Medicines (NASDAQ:BPMC) and lower its price target from $82.00 to $60.00. Shares of Blueprint Medicines are trading down 8.32%...
Via
Benzinga
10 Biggest Price Target Changes For Monday
June 13, 2022
RBC Capital reduced Tesla, Inc. (NASDAQ: TSLA) price target from $1,175 to $1,100. Tesla shares fell 3.7% to $670.89 in pre-market trading.
Via
Benzinga
91 Biggest Movers From Friday
June 13, 2022
Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto.
Via
Benzinga
44 Stocks Moving In Friday's Mid-Day Session
June 10, 2022
Gainers Cogent Biosciences, Inc. (NASDAQ: COGT) shares jumped 77% to $8.79 after the company reported initial data from its ongoing Phase 2 APEX clinical trial.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 10, 2022
June 10, 2022
Via
Benzinga
4 Analysts Have This to Say About Blueprint Medicines
June 10, 2022
Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Blueprint Medicines: Q1 Earnings Insights
May 03, 2022
Blueprint Medicines (NASDAQ:BPMC) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Scheduled For February 16, 2022
February 16, 2022
Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is projected to report quarterly loss at $0.38 per share on revenue of $331.16 million.
Via
Benzinga
What You Missed On Wall Street On Thursday
June 10, 2022
Here are our top five lists with the news and calls moving stocks, that you better not have missed yesterday...
Via
Talk Markets
Blueprint Stock Dives On The FDA's Tricky New Requirement For Its Leading Drug
June 09, 2022
The FDA had a suggestion for Blueprint's midstage systemic mastocytosis test.
Via
Investor's Business Daily
Bristol Myers Snaps Up Turning Point For $4.1 Billion In Cash — Is The Biotech Bear Dead?
June 03, 2022
Bristol Myers is moving deeper into the targeted oncology space.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2022
June 01, 2022
Upgrades
Via
Benzinga
10 Biggest Price Target Changes For Wednesday
June 01, 2022
Keybanc cut Ambarella, Inc. (NASDAQ: AMBA) price target from $160 to $120. Ambarella shares fell 5% to $81.00 in pre-market trading.
Via
Benzinga
What 3 Analyst Ratings Have To Say About Blueprint Medicines
May 19, 2022
Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings within the last quarter:
Via
Benzinga
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
May 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Earnings Preview: Blueprint Medicines
May 02, 2022
Blueprint Medicines (NASDAQ:BPMC) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Blueprint Medicines Q1 2022 Earnings Conference Call On May 3, 2022 At 08:30 AM ET
April 27, 2022
Blueprint Medicines (NASDAQ:BPMC) will host a conference call at 08:30 AM ET on May 3, 2022, to discuss Q1 2022 earnings results.
Via
Benzinga
Where Blueprint Medicines Stands With Analysts
April 13, 2022
Over the past 3 months, 6 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
After Encouraging Data, Blueprint Medicines Plans Combination Cohort In Tagrisso Resistant Lung Cancer
April 11, 2022
Blueprint Medicines Corp (NASDAQ: BPMC)
Via
Benzinga
Wednesdays With Wedbush: 3 Smid-Cap Biotech Stock Picks
March 09, 2022
Since the coronavirus pandemic began in early 2020, the FDA's plate has been full with reviews of COVID-19 vaccines and treatments. That has put the approval of many...
Via
Benzinga
What 5 Analyst Ratings Have To Say About Blueprint Medicines
March 01, 2022
Over the past 3 months, 5 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC) stock. These analysts are typically employed by large Wall Street banks and...
Via
Benzinga
Blueprint Medicines, Proteovant Collaboration For Protein Degrader Therapies
February 28, 2022
Blueprint Medicines Corporation (NASDAQ: BPMC) and Proteovant Therapeutics have entered a strategic collaboration for targeted protein degrader therapies....
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
March 01, 2022
During Tuesday's trading, 98 companies set new 52-week lows. Intriguing Points From Today's 52-Week Lows And Highs: JPMorgan Chase (NYSE:JPM) was the...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022
March 01, 2022
Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,...
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
February 25, 2022
During Friday's trading, 54 companies set new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company by market cap to hit a new 52-week...
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
February 28, 2022
On Monday morning, 66 companies achieved new lows for the year. Noteable 52-Week Lows: Gilead Sciences (NASDAQ:GILD) was the largest firm on a market cap basis to set a...
Via
Benzinga
Where Blueprint Medicines Stands With Analysts
February 17, 2022
Over the past 3 months, 5 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC) stock. These analysts are typically employed by large Wall Street banks and...
Via
Benzinga
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
February 16, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following...
Via
Benzinga
Earnings Preview: Blueprint Medicines
February 15, 2022
Blueprint Medicines (NASDAQ:BPMC) is set to give its latest quarterly earnings report on Wednesday, 2022-02-16. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
February 13, 2022
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.